SUVENBSESuven Life Sciences LtdHighNeutral
Announced Wed, 8 Jul · 12:51 IST

Suven allots 1.85 cr shares on warrant conversion; sets up Singapore WOS

Warrants ConvertedFund Raising View source PDF

SUVEN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+10.2%1-day move
₹317.50
prior close
₹321.75
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.1+0.1+0.9+0.8+10.2+12.3+13.1+9.9+12.5+2.2
Up moveDown movePending
AI summary

Board approved conversion of 1,85,70,133 warrants into equity shares at Rs 134 each to 17 non-promoter allottees, raising about Rs 248.84 crore. Paid-up equity capital rose to 28.26 crore shares. Also re-appointed Dr. Vajja Sambasiva Rao as Independent Director for 5 years from Jan 2027. Incorporated wholly owned subsidiary Suven Neurosciences Pte. Ltd. in Singapore with planned investment of USD 100 million for neurological therapeutics.

Likely market impact

Dilution from warrant conversion already priced in. Fresh capital strengthens balance sheet; Singapore WOS signals overseas push into neuro therapeutics.